Dec 12, 2018
Ocrevus (ocrelizumab, by Genentech) is now available through the National Health System (NHS) of Scotland to treat patients with relapsing-remitting multiple sclerosis (RRMS).
The decision by the Scottish Medicines Consortium (SMC) to approve Ocrevus’ inclusion for this patient group follows the recommendation made earlier by the U.K.’s National Institute for Health and Care Excellence (NICE).
“This is really welcome news for people with relapsing MS in Scotland, as it gives them access to a proven treatment alongside people in the rest of the U.K.,” Linden Muirhead, director of information and engagement at MS Trust, said in a news release.
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews